KR101203777B1 - 항-ｔｙｒｐ１ 항체 - Google Patents

항-ｔｙｒｐ１ 항체 Download PDF

Info

Publication number
KR101203777B1
KR101203777B1 KR1020107020296A KR20107020296A KR101203777B1 KR 101203777 B1 KR101203777 B1 KR 101203777B1 KR 1020107020296 A KR1020107020296 A KR 1020107020296A KR 20107020296 A KR20107020296 A KR 20107020296A KR 101203777 B1 KR101203777 B1 KR 101203777B1
Authority
KR
South Korea
Prior art keywords
antibody
antibodies
tyrp1
fragment
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107020296A
Other languages
English (en)
Korean (ko)
Other versions
KR20100113631A (ko
Inventor
시아오키앙 캉
폴 제이 발더레스
Original Assignee
임클론 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40790741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101203777(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 임클론 엘엘씨 filed Critical 임클론 엘엘씨
Publication of KR20100113631A publication Critical patent/KR20100113631A/ko
Application granted granted Critical
Publication of KR101203777B1 publication Critical patent/KR101203777B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020107020296A 2008-03-12 2009-03-11 항-ｔｙｒｐ１ 항체 Expired - Fee Related KR101203777B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6919908P 2008-03-12 2008-03-12
US61/069,199 2008-03-12
PCT/US2009/036739 WO2009114585A1 (en) 2008-03-12 2009-03-11 Anti-tyrp1 antibodies

Publications (2)

Publication Number Publication Date
KR20100113631A KR20100113631A (ko) 2010-10-21
KR101203777B1 true KR101203777B1 (ko) 2012-11-21

Family

ID=40790741

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107020296A Expired - Fee Related KR101203777B1 (ko) 2008-03-12 2009-03-11 항-ｔｙｒｐ１ 항체

Country Status (19)

Country Link
US (1) US7951370B2 (enExample)
EP (1) EP2268672A1 (enExample)
JP (1) JP2011516041A (enExample)
KR (1) KR101203777B1 (enExample)
CN (1) CN101970500B (enExample)
AR (1) AR070821A1 (enExample)
AU (1) AU2009222998B2 (enExample)
BR (1) BRPI0909633A2 (enExample)
CA (1) CA2718289A1 (enExample)
CL (1) CL2009000567A1 (enExample)
EA (1) EA019517B1 (enExample)
IL (1) IL207581A0 (enExample)
MX (1) MX2010010021A (enExample)
NZ (1) NZ587305A (enExample)
PE (1) PE20091679A1 (enExample)
TW (1) TWI384997B (enExample)
UA (1) UA99339C2 (enExample)
WO (1) WO2009114585A1 (enExample)
ZA (1) ZA201006099B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2167540B1 (en) * 2007-06-29 2018-02-14 F. Hoffmann-La Roche AG Heavy chain mutant leading to improved immunoglobulin production
MX2016010177A (es) 2014-02-07 2017-01-09 Dong Wha Pharm Co Ltd Composicion adyuvante anticancerosa que contiene promotor de la expresion de rip3 como principio activo, metodo para la deteccion de adyuvante anticanceroso que potencia la sensibilidad al farmaco anticanceroso mediante la estimulacion de la expresion de rip3 y metodo para controlar la sensibilidad del farmaco anticanceroso.
DK3233907T3 (da) 2014-12-19 2021-06-07 Genmab As Bispecifikke heterodimeriske proteiner hos gnavere
RU2630647C1 (ru) * 2016-05-27 2017-09-11 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
GB201613167D0 (en) 2016-07-29 2016-09-14 Univ Southampton Cancer and b-cell related disease therapy
WO2018075586A1 (en) * 2016-10-18 2018-04-26 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof
MX2019015053A (es) * 2017-06-14 2020-02-13 Adicet Bio Inc Anticuerpos capaces de unirse a hla-a2/tyrd de forma restringida por hla y usos de estos.
RU2687609C1 (ru) * 2018-05-30 2019-05-15 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Гуманизированное антитело к конформационному эпитопу сз компонента комплемента человека
EP3856775B9 (en) 2018-09-27 2025-01-22 Autolus Limited Chimeric antigen receptor
EP3876988A4 (en) * 2018-11-09 2022-11-09 Beth Israel Deaconess Medical Center THERAPIES TARGETED AGAINST CDCP1
TWI881476B (zh) * 2018-12-21 2025-04-21 瑞士商赫孚孟拉羅股份公司 結合cd3之抗體
CN114765980A (zh) * 2019-09-06 2022-07-19 加利福尼亚大学董事会 用于治疗癌症的嵌合抗原受体及相关方法和组合物
WO2023094569A1 (en) * 2021-11-26 2023-06-01 F. Hoffmann-La Roche Ag Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
WO2025104289A1 (en) 2023-11-17 2025-05-22 Medincell S.A. Antineoplastic combinations
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798790A (en) 1985-07-18 1989-01-17 Sloan-Kettering Institute Monoclonal antibody specific for a pigmentation associated antigen
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
EP0362371A4 (en) 1988-04-15 1990-10-24 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
ATE119198T1 (de) 1988-04-16 1995-03-15 Celltech Ltd Verfahren zur herstellung von proteinen mittels rekombinanter dna.
IE910820A1 (en) 1990-03-22 1991-09-25 Sloan Kettering Inst Cancer Gp75 as a tumor vaccine for melanoma
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
AU6171196A (en) * 1995-06-07 1996-12-30 Sloan-Kettering Institute For Cancer Research Therapeutic uses of ta99
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
BR9815289A (pt) * 1997-11-14 2001-12-26 Euro Celtique Sa Imunoglobulina modificada, molécula, ácidonucleico isolado, célula contendo o mesmo, animalnão-humano recombinante, composiçãofarmacêutica, composição de vacina, processospara identificar ou medir ou detectar um antìgenode câncer, um antìgeno de um agente de doençainfecciosa, um ligante, e um receptor em umaamostra a ser testada, kits para detecção de umantìgeno de câncer, de um antìgeno de um agentede doença infecciosa, de um receptor celular paraum agente de doença infecciosa, de um ligante, e deum antìgeno de câncer, processos de diagnósticoou de exame para a presença de ou umapredisposição para desenvolvimento de um câncertipificado pela presença aumentada de umantìgeno de câncer, e para a presença de umagente de doença infecciosa, processos detratamento ou de prevenção de um câncertipificado pela presença de um antìgeno de câncer,de uma doença infecciosa tipificada pela presençade um antìgeno de agente de doença infecciosa, ede uma doença causada por um agente de doençainfecciosa que se liga em um receptor celular,processos para modulação de atividade de umprimeiro membro de um par de ligação, processo deprodução de uma imunoglobulina modificada,processo de produção de um ácido nucleicocodificador de imunoglobulina modificada, e, ácidonucleico isolado
NZ522847A (en) * 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
WO2006047340A2 (en) * 2004-10-22 2006-05-04 Amgen Inc. Methods for refolding of recombinant antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Human Antibody. 2007. 126-136.*

Also Published As

Publication number Publication date
CL2009000567A1 (es) 2010-02-26
KR20100113631A (ko) 2010-10-21
UA99339C2 (ru) 2012-08-10
CN101970500A (zh) 2011-02-09
TWI384997B (zh) 2013-02-11
AU2009222998B2 (en) 2013-05-23
AR070821A1 (es) 2010-05-05
NZ587305A (en) 2012-05-25
EA019517B1 (ru) 2014-04-30
EP2268672A1 (en) 2011-01-05
AU2009222998A1 (en) 2009-09-17
IL207581A0 (en) 2010-12-30
MX2010010021A (es) 2011-02-15
US7951370B2 (en) 2011-05-31
CN101970500B (zh) 2013-08-14
US20090232823A1 (en) 2009-09-17
JP2011516041A (ja) 2011-05-26
CA2718289A1 (en) 2009-09-17
EA201071068A1 (ru) 2011-04-29
BRPI0909633A2 (pt) 2015-09-22
PE20091679A1 (es) 2009-11-04
WO2009114585A1 (en) 2009-09-17
TW200944232A (en) 2009-11-01
ZA201006099B (en) 2012-01-25

Similar Documents

Publication Publication Date Title
KR101203777B1 (ko) 항-ｔｙｒｐ１ 항체
JP7143452B2 (ja) ＣＤ４７とＳＩＲＰａの相互作用を遮断できる抗体及びその応用
TWI402078B (zh) 抗ｃｓｆ－１ｒ抗體
AU2007324509B2 (en) Novel antiproliferation antibodies
CN109311978B (zh) Dsg2单克隆抗体和其用途
KR20240162588A (ko) Cd3 및 bcma에 대한 항체, 및 이로부터 제조된 이중특이적 결합 단백질
JP2011516041A5 (enExample)
CN114907479B (zh) 抗cd112r抗体及其用途
AU2019233507B2 (en) Treatment of head and neck cancer
KR20250035542A (ko) 항-cldn18.2 항체 및 이의 약제학적 조성물 및 용도
CN113214402B (zh) 分离的抗原结合蛋白及其应用
TW202146459A (zh) 抗pdl1×egfr的雙特異性抗體
KR20250084976A (ko) 항cd16a 항체 및 이의 적용
EP4417622A1 (en) Anti-cd26 antibody and use thereof
EP4219553A1 (en) Anti-tigit antibody and double antibody and their application
KR20240058017A (ko) 항-vsig4 항체를 포함하는 항암용 조성물
WO2024054418A1 (en) Sequence optimization of a pd1 blocking antibody
HK40089230A (zh) 药物组合物及用途
JP2023534726A (ja) 多発性骨髄腫の治療に使用するための抗ｄｒ５抗体と免疫調節イミド薬との併用

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20151116

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20151116